<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689258</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-C2015-203</org_study_id>
    <nct_id>NCT02689258</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery</brief_title>
  <official_title>A Phase 2, Randomized, Controlled Evaluation of the Efficacy and Safety of HTX-011 or HTX-002 for Post-Operative Analgesia Following Abdominoplasty Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <brief_summary>
    <textblock>
      A Phase 2, Randomized, Controlled Evaluation of the Efficacy and Safety of HTX-011 or HTX-002&#xD;
      for Post-Operative Analgesia Following Abdominoplasty Surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed Pain Intensity Scores collected over 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Part A Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of HTX-011A by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of HTX-011B by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of HTX-011B by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg of HTX-011B by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 300 mg of HTX-011B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011B</intervention_name>
    <arm_group_label>Part A Cohort C</arm_group_label>
    <arm_group_label>Part A Cohort D</arm_group_label>
    <arm_group_label>Part A Cohort E</arm_group_label>
    <arm_group_label>Part B Cohort A</arm_group_label>
    <arm_group_label>Part C Cohort A</arm_group_label>
    <arm_group_label>Part D Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A Cohort B</arm_group_label>
    <arm_group_label>Part B Cohort A</arm_group_label>
    <arm_group_label>Part C Cohort A</arm_group_label>
    <arm_group_label>Part D Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011A</intervention_name>
    <arm_group_label>Part A Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-002</intervention_name>
    <arm_group_label>Part B Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine HCl</intervention_name>
    <arm_group_label>Part C Cohort A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to be considered eligible to participate&#xD;
        in the study:&#xD;
&#xD;
          1. Be scheduled to undergo abdominoplasty surgery that is amenable to treatment with a&#xD;
             long acting local anesthetic as per the anesthesia protocol&#xD;
&#xD;
          2. Be American Society of Anesthesiology (ASA) physical Class I or II&#xD;
&#xD;
          3. Subjects 18 years of age or older&#xD;
&#xD;
          4. Have clinical laboratory values that are within normal limits (WNL); subjects with&#xD;
             AST/ALT &lt; 3 x ULN, and/or creatinine &lt; 2 x ULN are acceptable.&#xD;
&#xD;
          5. Have a body mass index â‰¤ 30 kg/m2&#xD;
&#xD;
          6. Female subjects are eligible only if all of the following apply:&#xD;
&#xD;
               -  Not pregnant (female subject of child bearing potential must have a negative&#xD;
                  serum pregnancy tests at screening and negative urine pregnancy test before&#xD;
                  surgery)&#xD;
&#xD;
               -  Not lactating&#xD;
&#xD;
               -  Not planning to become pregnant during the study&#xD;
&#xD;
               -  Be surgically sterile; or at least two years post-menopausal; or have a&#xD;
                  monogamous partner who is surgically sterile; or is practicing double-barrier&#xD;
                  contraception; or practicing abstinence (must agree to use double-barrier&#xD;
                  contraception in the event of sexual activity); or using an insertable,&#xD;
                  injectable, transdermal, or combination oral contraceptive approved by the FDA&#xD;
                  for greater than 2 months prior to screening visits and commits to the use of an&#xD;
                  acceptable form of birth control for the duration of the study&#xD;
&#xD;
          7. Male subjects must be surgically sterile (biologically or surgically) or commit to the&#xD;
             use of a reliable method of birth control for the duration of the study&#xD;
&#xD;
          8. Does NOT have, as determined by the investigator or the study's medical monitor, a&#xD;
             history or clinical manifestations of significant renal, hepatic, cardiovascular,&#xD;
             metabolic, neurologic, psychiatric, or other condition that would preclude&#xD;
             participation in the study&#xD;
&#xD;
          9. Must be able to understand study procedures and be willing to comply and give informed&#xD;
             consent for the conduct of all study procedures, using an IRB approved consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from participating in the&#xD;
        study:&#xD;
&#xD;
          1. Have a contraindication or be allergic to any medication to be used during the trial&#xD;
             period&#xD;
&#xD;
          2. Have another painful physical condition that, in the opinion of the investigator, may&#xD;
             confound the assessments of post-operative pain&#xD;
&#xD;
          3. Have a history of migraine or frequent headaches, seizures, or are currently taking&#xD;
             anticonvulsants&#xD;
&#xD;
          4. Currently taking analgesics for a chronically painful condition, or has taken long&#xD;
             acting opioids within 3 days of surgery, or taken any opioids within 24 hours of&#xD;
             surgery&#xD;
&#xD;
          5. Previous abdominal surgery, as determined by the investigator, that would preclude&#xD;
             participation in the study&#xD;
&#xD;
          6. Subjects that require liposuction as part of the abdominoplasty procedure in Part A of&#xD;
             the protocol&#xD;
&#xD;
          7. Subjects that are to have ancillary procedures performed during the abdominoplasty&#xD;
             surgery that are unrelated to the abdominal area (breast reduction, breast&#xD;
             augmentation, etc.)&#xD;
&#xD;
          8. Subjects unable to discontinue medications that have not been at a stable dose for at&#xD;
             least 14 days prior to the scheduled abdominoplasty procedure and before dosing with&#xD;
             investigational product&#xD;
&#xD;
          9. Subjects taking the following medications; anticonvulsants, sedatives (including&#xD;
             benzodiazepines) corticosteroids (by any means of administration), nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDS) within 24 hours of study drug dosing, morphine,&#xD;
             monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics,&#xD;
             or serotonin-norepinephrine reuptake inhibitors (SNRIs). Gabapentin and pregabalin are&#xD;
             not permitted&#xD;
&#xD;
         10. Have a known or suspected history of alcohol or drug abuse&#xD;
&#xD;
         11. Have positive results on the alcohol breath test indicative of alcohol abuse or urine&#xD;
             drug screen indicative of illicit drug use (unless results can be explained by a&#xD;
             current prescription or acceptable over-the-counter medication at screening as&#xD;
             determined by the investigator). The urine drug screen prior to surgery must be&#xD;
             negative&#xD;
&#xD;
         12. Have evidence of a clinically significant 12-lead ECG abnormality according to the&#xD;
             judgment of the investigator&#xD;
&#xD;
         13. Have received any investigational product within 30 days before start of study&#xD;
&#xD;
         14. Have previously received HTX-011 in clinical trials&#xD;
&#xD;
         15. Experiences a clinically significant event during surgery prior to the administration&#xD;
             of the investigational product (e.g., excessive bleeding, hemodynamic instability)&#xD;
             that would render the subject medically unstable, complicate their post-surgical&#xD;
             course, or significantly increase the risk of study drug administration as per the&#xD;
             judgment of the investigator. This will result in the subject being reported as&#xD;
             randomized, not treated.&#xD;
&#xD;
         16. Subjects with sleep apnea or are on home continuous positive airway pressure (CPAP)&#xD;
&#xD;
         17. Subjects who are receiving oxygen therapy at the time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <disposition_first_submitted>June 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2018</disposition_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 11, 2021</submitted>
    <submission_canceled>June 11, 2021</submission_canceled>
    <submitted>June 14, 2021</submitted>
    <returned>July 2, 2021</returned>
    <submitted>October 15, 2021</submitted>
    <returned>November 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

